- £92M will fund an aseptic sterile facility at Barnard Castle for biopharmaceuticals.
- £110M will build a new facility at Montrose for respiratory active ingredients.
- £74M will expand Ware's Ellipta respiratory inhaler manufacturing.
- The investment supports current jobs and creates new opportunities.
Investment Overview
GSK announced a £275 million investment across three UK manufacturing sites to enhance production and support the delivery of innovative respiratory and large molecule biological medicines, primarily for export.
Site-Specific Investments
Barnard Castle in County Durham will receive £92 million to construct an aseptic sterile facility for manufacturing existing and new biopharmaceutical assets. This site employs 1,100 people and supplies nearly half a million product packs daily to 140 global markets.
Montrose in Angus, Scotland, will benefit from a £110 million investment to build a state-of-the-art facility for manufacturing respiratory active ingredients. This site employs over 450 staff and produces active ingredients for respiratory, HIV, and vaccine products.
Ware in Hertfordshire will see a £74 million investment to expand the manufacturing capacity of the Ellipta respiratory inhaler. This site employs 1,200 staff and focuses on innovative respiratory products.
Employment Impact
The investments will support current employment at the three sites and are expected to create new job opportunities, including those associated with the construction of the new facilities.
Strategic Importance
GSK's decision to invest in the UK is influenced by the country's skilled workforce, technological and scientific capabilities, infrastructure, and competitive corporate tax system, including the Patent Box, which incentivizes R&D and related manufacturing.
